U.S. Markets closed

Vaxcyte, Inc. (PCVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W
50.47+1.05 (+2.12%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close49.42
Open48.89
Bid37.35 x 800
Ask50.73 x 800
Day's Range48.89 - 52.15
52 Week Range17.80 - 55.04
Volume3,294,148
Avg. Volume203,538
Market Cap2.57B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.50
  • We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
    Simply Wall St.

    We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference

    FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 11:00 a.m. ET.A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.About Vaxcyte Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains, including newly emerging strains responsible for IPD and antibiotic resistance; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.Contact: Andrew Guggenhime, Chief Financial Officer & Chief Business Officer Vaxcyte, Inc. 650-837-0111 investors@vaxcyte.com

  • Dow Jones Edges Higher In New Bid For 28,000; Tesla, AMAT Stock Lead Nasdaq
    Investor's Business Daily

    Dow Jones Edges Higher In New Bid For 28,000; Tesla, AMAT Stock Lead Nasdaq

    The Dow Jones held a modest gain late Friday, buoyed by a 2% gain for Boeing stock. A strong earnings report lifted AMAT stock in the Nasdaq 100.